---
layout: post
title: "【图解年报】易明医药：2021年归母净利润小幅增长3.4%，约为4248万元"
date: 2022-04-21 21:06:21 +0800
categories: dongfangcaifuChoiceshuju
tags: 东方财富Choice数据新闻
---
<p>易明医药于2022年4月22日披露年报，公司2021年实现营业总收入7.3亿，同比增长20.4%；实现归母净利润4247.6万，同比增长3.4%；每股收益为0.22元。</p><img id="image7" class="autoimg" src="https://dfscdn.dfcfw.com/download/D2B687977B65E5B3BB07C37BE49484D1BA_w800h400.jpg" alt=""><p style="color:#61768C;font-size:0.9em;"></p><img id="image9" class="autoimg" src="https://dfscdn.dfcfw.com/download/D27FBFC544C32315B6EEA0CEAD23CD637E_w800h400.jpg" alt=""><p><strong>期间费用为2.3亿，营业成本为4.6亿</strong></p><p>公司2021年营业成本4.6亿，同比增长20.5%，高于营业收入20.4%的增速，导致毛利率下降0.1%。期间费用率为31.5%，较上年升高0.7个百分点。</p><img id="image12" class="autoimg" src="https://dfscdn.dfcfw.com/download/D21FE51396CCD263BE368E303F95B8252D_w800h400.jpg" alt=""><p><strong>本期“瓜蒌皮注射液”营收贡献较大 </strong></p><p>从业务结构来看，“瓜蒌皮注射液”是企业营业收入的主要来源。具体而言，“瓜蒌皮注射液”营业收入为3.3亿，营收占比为45.8%，毛利率为8.3%。</p><img id="image15" class="autoimg" src="https://dfscdn.dfcfw.com/download/D283F2598C476C62BFF921A39A0A146C8D_w800h400.jpg" alt=""><img id="image17" class="autoimg" src="https://dfscdn.dfcfw.com/download/D21CC3F36907A98223F0EA373B9CA43E96_w800h400.jpg" alt=""><p style="font-weight:bold;"></p><p style="margin: 10px 0; color: #999">免责声明：本文基于大数据生产，仅供参考，不构成任何投资建议，据此操作风险自担。</p><style>.autoimg {display: block;border: 0;max-width: 100%;margin: 0 auto;} .tbl {border-collapse: collapse;border-spacing: 0;text-align: center;width: 100% !important;} .tbl tr th, .tbl tr td {border: 1px solid #d8e6ff;padding: 5px;text-align: center;} .tbl tr th {color: #fff;background-color: #1c65b0;vertical-align: middle;} .tbl tr td {color: #000;background-color: #fff;} .imgtitle {text-indent: 0;text-align: center;color: #2395F1;} .autosrc {color: #999;display: block;text-align: center;margin-bottom: 5px;}</style>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204212352348141>

[返回东方财富Choice数据新闻](//finews.withounder.com/category/dongfangcaifuChoiceshuju.html)｜[返回首页](//finews.withounder.com/)